MA23942A1 - Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation - Google Patents

Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation

Info

Publication number
MA23942A1
MA23942A1 MA24317A MA24317A MA23942A1 MA 23942 A1 MA23942 A1 MA 23942A1 MA 24317 A MA24317 A MA 24317A MA 24317 A MA24317 A MA 24317A MA 23942 A1 MA23942 A1 MA 23942A1
Authority
MA
Morocco
Prior art keywords
preparation
formulation containing
novel formulation
containing paroxetine
paroxetine
Prior art date
Application number
MA24317A
Other languages
English (en)
Inventor
Philip Elder David
Stanley Leonard Graham
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10777960&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA23942(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA23942A1 publication Critical patent/MA23942A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyurethanes Or Polyureas (AREA)
MA24317A 1995-07-20 1996-07-18 Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation MA23942A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9514842.5A GB9514842D0 (en) 1995-07-20 1995-07-20 Novel formulation

Publications (1)

Publication Number Publication Date
MA23942A1 true MA23942A1 (fr) 1997-04-01

Family

ID=10777960

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24317A MA23942A1 (fr) 1995-07-20 1996-07-18 Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation

Country Status (41)

Country Link
EP (2) EP0839039B2 (fr)
JP (2) JP3922392B2 (fr)
KR (1) KR100468351B1 (fr)
CN (2) CN1117567C (fr)
AP (1) AP1052A (fr)
AR (1) AR003463A1 (fr)
AT (1) ATE253361T1 (fr)
AU (1) AU6659196A (fr)
BG (1) BG64076B1 (fr)
BR (1) BR9609857A (fr)
CA (2) CA2227298C (fr)
CY (1) CY2408B1 (fr)
CZ (1) CZ294110B6 (fr)
DE (1) DE69630603T3 (fr)
DK (1) DK0839039T4 (fr)
DZ (1) DZ2074A1 (fr)
EA (2) EA003508B1 (fr)
EG (1) EG23934A (fr)
ES (1) ES2208757T5 (fr)
GB (1) GB9514842D0 (fr)
HK (1) HK1010494A1 (fr)
HU (1) HU228853B1 (fr)
IL (1) IL122940A0 (fr)
MA (1) MA23942A1 (fr)
MX (1) MX9800571A (fr)
MY (1) MY141373A (fr)
NO (1) NO315637B1 (fr)
NZ (1) NZ315006A (fr)
OA (1) OA10652A (fr)
PE (1) PE16098A1 (fr)
PL (1) PL184987B1 (fr)
PT (1) PT839039E (fr)
RO (1) RO119119B1 (fr)
SI (1) SI0839039T2 (fr)
SK (1) SK284117B6 (fr)
TR (1) TR199800077T1 (fr)
TW (1) TW464513B (fr)
UA (1) UA68328C2 (fr)
UY (3) UY24288A1 (fr)
WO (1) WO1997003670A1 (fr)
ZA (1) ZA966148B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
CA2293247C (fr) * 1997-06-10 2005-04-12 Synthon B.V. Composes 4-phenylpiperidine
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
KR100412327B1 (ko) 1997-07-01 2003-12-31 화이자 인코포레이티드 서트랄린 염 및 서트랄린의 서방성 투여형
GB9808479D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
JP4854115B2 (ja) 1999-03-12 2012-01-18 エイシカ ファーマシューティカルス リミテッド 無水パロキセチン用安定製剤形
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
DE60035579T2 (de) * 1999-05-20 2008-04-17 Elan Corp. Plc Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
WO2000078290A2 (fr) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Nouvelle preparation
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
CA2457385A1 (fr) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Preparation enterique de fluoxetine
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
SG147450A1 (en) 2003-10-29 2008-11-28 Wyeth Corp Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
US20050209218A1 (en) * 2004-02-13 2005-09-22 Meyerson Laurence R Methods and compositions for the treatment of psychiatric conditions
WO2005107716A1 (fr) * 2004-03-25 2005-11-17 Cadila Healthcare Limited Comprimes a liberation lente a base de paroxetine comprenant un noyau et un revetement
AU2006274565B2 (en) * 2005-08-02 2012-05-17 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
US20090130206A1 (en) * 2006-05-09 2009-05-21 Umesh Nandkumar Khatavkar Controlled Release Compositions of an Antidepressant Agent
KR100885029B1 (ko) 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2009006299A2 (fr) * 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Systèmes à multiples particules
CA2698808A1 (fr) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthese de benzo[d][1,3]dioxoles et de catechols deuteries, ainsi que de leurs derives
TW201010743A (en) 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
CN102639117A (zh) * 2009-08-24 2012-08-15 H.隆德贝克有限公司 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物
CN103371982A (zh) * 2012-04-20 2013-10-30 王进京 盐酸帕罗西汀肠溶控释片新型处方组成及制备方法
CN104411368A (zh) * 2012-07-09 2015-03-11 荷兰联合利华有限公司 光防护性个人护理组合物
CN103550182B (zh) * 2013-10-29 2015-04-08 吉林省东盟制药有限公司 一种肠溶缓释组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
DE69119217T2 (de) * 1990-08-21 1996-10-31 Theratech Inc Zusammensetzungen zur kontrollierten freigabe
WO1992009281A2 (fr) * 1990-11-24 1992-06-11 Beecham Group Plc Utilisation de paroxetine pour le traitement de la demence senile, la boulimie, la migraine ou l'anorexie
EP0720478A1 (fr) * 1991-05-07 1996-07-10 Dynagen, Inc. Systeme d'administration a liberation prolongee regulee utilise pour cesser de fumer
JPH05139964A (ja) * 1991-11-14 1993-06-08 Takada Seiyaku Kk 塩酸メキシレチン腸溶性製剤
ES2168290T3 (es) * 1993-11-23 2002-06-16 Euro Celtique Sa Metodo para preparar una composicion de liberacion sostenida.
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
CA2143070C (fr) * 1994-02-22 2001-12-18 Pankaj Modi Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
JP3768536B2 (ja) * 1995-04-03 2006-04-19 アボツト・ラボラトリーズ 低温溶融性薬物と制御放出のための添加物との均質混合物

Also Published As

Publication number Publication date
EA199800140A1 (ru) 1998-10-29
EP1382337A1 (fr) 2004-01-21
JP3922392B2 (ja) 2007-05-30
PL324553A1 (en) 1998-06-08
EP0839039B1 (fr) 2003-11-05
NO315637B1 (no) 2003-10-06
TR199800077T1 (xx) 1998-05-21
AR003463A1 (es) 1998-08-05
KR19990029076A (ko) 1999-04-15
CN1515257A (zh) 2004-07-28
UY24288A1 (es) 1997-01-16
HUP9900299A3 (en) 1999-11-29
CA2227298A1 (fr) 1997-02-06
IL122940A0 (en) 1998-08-16
MX9800571A (es) 1998-04-30
ATE253361T1 (de) 2003-11-15
NO980240D0 (no) 1998-01-19
HK1010494A1 (en) 1999-06-25
JP2006265258A (ja) 2006-10-05
DK0839039T4 (da) 2007-10-08
DE69630603D1 (de) 2003-12-11
DZ2074A1 (fr) 2002-07-22
CZ294110B6 (cs) 2004-10-13
EA003775B1 (ru) 2003-08-28
BG102259A (en) 1998-09-30
MY141373A (en) 2010-04-16
ES2208757T5 (es) 2007-12-16
NZ315006A (en) 2000-01-28
CN1117567C (zh) 2003-08-13
OA10652A (en) 2002-09-18
CA2445678C (fr) 2009-11-24
EA003508B1 (ru) 2003-06-26
RO119119B1 (ro) 2004-04-30
CN1195986A (zh) 1998-10-14
EP0839039B2 (fr) 2007-06-06
UY24436A1 (es) 2001-08-27
NO980240L (no) 1998-01-20
PE16098A1 (es) 1998-04-16
EA200100022A1 (ru) 2001-06-25
SI0839039T2 (sl) 2007-10-31
EG23934A (en) 2008-01-14
CA2227298C (fr) 2003-12-09
GB9514842D0 (en) 1995-09-20
DE69630603T3 (de) 2008-01-03
WO1997003670A1 (fr) 1997-02-06
SI0839039T1 (en) 2004-04-30
UA68328C2 (en) 2004-08-16
CZ18398A3 (cs) 1998-06-17
JPH11509539A (ja) 1999-08-24
HUP9900299A2 (hu) 1999-09-28
AP1052A (en) 2002-03-21
SK284117B6 (sk) 2004-09-08
PT839039E (pt) 2004-03-31
BR9609857A (pt) 1999-03-16
CA2445678A1 (fr) 1997-02-06
HU228853B1 (en) 2013-06-28
DK0839039T3 (da) 2004-03-08
DE69630603T2 (de) 2004-09-23
ZA966148B (en) 1998-01-19
ES2208757T3 (es) 2004-06-16
AU6659196A (en) 1997-02-18
AP9801177A0 (en) 1998-01-31
SK5398A3 (en) 1998-07-08
CN1282456C (zh) 2006-11-01
UY26242A1 (es) 2001-01-31
TW464513B (en) 2001-11-21
KR100468351B1 (ko) 2005-03-16
EP0839039A1 (fr) 1998-05-06
BG64076B1 (bg) 2003-12-31
PL184987B1 (pl) 2003-01-31
CY2408B1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
MA23942A1 (fr) Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA23831A1 (fr) Derives de quinazoline, procede pour leur preparation et composition les contenant
MA26430A1 (fr) 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2740136B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA23866A1 (fr) N-(indole-2-carbonyl)-glycinamides substitues, procede pour leur preparation et compositions les contenant
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA22521A1 (fr) Compositions anti- transpirantes en batonnets-gels contenant un derive de la 2-oxazolidinone, et procede pour leur preparation
MA26451A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26432A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA24469A1 (fr) Derives d'acide arylsulfonyhydroxamique, procede pour leur preparation et compositions les contenant
MA26581A1 (fr) Forme hydratee nouvelle d'un derive de thiazolidine-dione, procede pour sa preparation et composition pharmaceutique la contenant
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
FR2735777B1 (fr) Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
MA26417A1 (fr) Azetidines, procede pour leur preparation, et compositions pharmaceutiques les contenant
FR2738245B1 (fr) Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
MA26582A1 (fr) Derives de thiazolidinedione nouveau, procede pour sa preparation et composition pharmaceutique le contenant
FR2569702B1 (fr) Nouvelle 4'-deschlororebeccamycine, composition pharmaceutique la contenant et procede pour sa preparation
MA26609A1 (fr) Derives de retiferol, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
FR2728901B1 (fr) Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant